Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 single-arm open-label multicenter study of human prothrombin complex for on-demand treatment of hemophilia B
CTR20244076Phase 3Completed
- Sponsor
- Sinopharm Guizhou Blood Products
- Start
- Nov 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of prothrombin complex concentrate, human in hemophilia B (HB), sponsored by Sinopharm Guizhou Blood Products. Primary endpoint: Hemostatic effectiveness for bleeding episodes. Started Nov 2024; status: completed.
02
Drugs
prothrombin complex concentrate, human
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on CTR20244076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244076.